Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York.
Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York.
J Am Acad Dermatol. 2019 Jan;80(1):27-40. doi: 10.1016/j.jaad.2018.06.057. Epub 2018 Jul 11.
Psoriasis is a systemic inflammatory disease associated with increased risk of comorbidities, such as psoriatic arthritis, Crohn's disease, malignancy, obesity, and cardiovascular diseases. These factors have a significant impact on the decision to use one therapy over another. The past decade has seen a paradigm shift in our understanding of the pathogenesis of psoriasis that has led to identification of new therapeutic targets. Several new drugs have gained approval by the US Food and Drug Administration, expanding the psoriasis armamentarium, but still a large number of patients continue to be untreated or undertreated. Treatment regimens for psoriasis patients should be tailored to meet the specific needs based on disease severity, the impact on quality of life, the response to previous therapies, and the presence of comorbidities. The first article in this continuing medical education series focuses on specific comorbidities and provides insights to choose appropriate systemic treatment in patients with moderate to severe psoriasis.
银屑病是一种全身性炎症性疾病，与多种合并症的发生风险增加相关，如银屑病关节炎、克罗恩病、恶性肿瘤、肥胖和心血管疾病。这些因素对选择一种治疗方法而不是另一种治疗方法有重大影响。过去十年，我们对银屑病发病机制的认识发生了重大转变，这导致了新的治疗靶点的确定。一些新的药物已获得美国食品和药物管理局的批准，扩大了银屑病的治疗选择，但仍有大量患者未得到治疗或治疗不足。银屑病患者的治疗方案应根据疾病严重程度、对生活质量的影响、对既往治疗的反应以及合并症的存在，量身定制，以满足特定需求。本继续教育系列的第一篇文章重点介绍了特定的合并症，并为中度至重度银屑病患者选择合适的系统治疗提供了见解。
